Reported 3 months ago
In its second quarter results, Pfizer (PFE) exceeded revenue and earnings expectations while raising its full-year outlook. Similarly, Merck (MRK) also surpassed estimates but adjusted its profit guidance downwards. The discussion highlights key factors for both companies, including developments in cancer therapies and product pipelines.
Source: YAHOO